Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Sensile Medical Enters into an Agreement with scPharmaceuticals

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
The SenseCore technology offers opportunities for improved therapy outcomes and healthcare cost reduction.

Sensile Medical AG has entered into a strategic partnership and supply agreement with scPharmaceuticals LLC to develop and manufacture an automated patch pump that delivers furosemide subcutaneously.

Furosemide is a diuretic that forms the cornerstone of heart failure therapy and is currently used in tablet form or in solution for intravenous administration. scPharmaceuticals has developed a proprietary subcutaneous formulation of furosemide and will use Sensile Medical’s patented SenseCore technology platform to deliver the drug in a patient-friendly and automated way. scPharmaceuticals will start its late-stage clinical development phase in the near future and expects to submit the New Drug Application for the furosemide drug device combination not later than Q1 of 2015.

“We are very pleased to enter this collaboration with scPharmaceuticals” said Derek Brandt, CEO of Sensile Medical. “We believe that our micro pump technology has the potential to address some important therapeutic and economic challenges that the medical community is facing today. “

“The Affordable Care Act has created an urgent need for novel therapies that offer benefits comparable to those achieved by intravenously administered drugs in the hospital, but which can be administered anytime anywhere by the patient”, said Pieter Muntendam, MD, President and CEO of scPharmaceuticals, “The SenseCore Micro-Pump technology stands out because of its precision and the unique and cost-effective two component design.”

Under the terms of the agreement, Sensile Medical will design, develop, and manufacture patch pumps for scPharmaceuticals’ proprietary subcutaneous formulation of furosemide. Furthermore, it establishes a strategic partnership between Sensile Medical and scPharmaceuticals to work together to develop further medications utilizing Sensile’s technology platform. Terms of the agreement were not disclosed.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos